WHO Issues New Clinical Advice On Treating Covid-19 Patients

Geneva : The World Health Organization (WHO) issued fresh clinical advice on Tuesday for treating COVID-19 patients, including those displaying persistent symptoms after recovery, and also said it advised using low-dose anti-coagulants to prevent blood clots.

“The other things in the guidance that are new are that COVID-19 patients at home should have the use of pulse oximetry, that’s measuring the oxygen levels, so you can identify whether somewhat at home is deteriorating and would be better off having hospital care,” WHO spokeswoman Margaret Harris told a U.N. briefing in Geneva.

The WHO advised clinicians to put patients into the awake prone position, on their front, shown to improve the oxygen flow, she said.

“Also we recommend, we suggest the use, of low-dose anti-coagulents to prevent blood clots forming in blood vessels. We suggest the use of lower doses rather than higher doses because higher doses may lead to other problems,” Harris said.

She added that a WHO-led team of independent experts, currently in the central Chinese city of Wuhan where the first human cases were detected in December 2019, is due to leave quarantine in the next two days to pursue its work with Chinese researchers on the virus origins.

She declined to commment on reports of delays in roll-out of vaccines in the European Union. She said she had no specific data and the WHO’s priority was for health workers in all countries to be vaccinated in the first 100 days of the year.

AstraZeneca, which developed its shot with Oxford University, told the EU on Friday it could not meet agreed supply targets up to the end of March.

Related Posts

Commissioner FDA reviews enforcement measures

Srinagar: Commissioner, Food & Drugs Administration (FDA), Jammu & Kashmir, Khalid Jahangir on Thursday held an introductory meeting with senior officers and field functionaries of Drug and Food Wing of the…

Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Karnataka High Court Ashwagandha ruling offers interim relief to supplement makers challenging the FSSAI advisory on Ashwagandha extracts. The Karnataka High Court has stayed an advisory issued by the Food…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Commissioner FDA reviews enforcement measures

Commissioner FDA reviews enforcement measures

Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

Piramal Pharma Gets 3 USFDA Observations at US Facility

Piramal Pharma Gets 3 USFDA Observations at US Facility

Eli Lilly pauses Indian obesity awareness campaign after regulatory notices

Eli Lilly pauses Indian obesity awareness campaign after regulatory notices